Lupin 2024

Dr. Daniel Holsworth

Leading Edge names Dr. Holsworth as CSO to head up clinical CBD research

Leading Edge names Dr. Holsworth as CSO to head up clinical CBD research

HENDERSON, Nev. – Leading Edge Pharms (LEP) a biotechnology company developing novel cannabinoid therapies and innovative delivery systems, announced Tuesday that Dr. Daniel Holsworth has been appointed chief science officer (CSO). Dr. Holsworth’s appointment signals LEP’s further commitment to providing clinically supported CBD-based solutions for topical pain relief and inflammatory skin conditions. “One of our

PP_1170x120_10-25-21